NCT02710708已完成4 期
Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 1,921
- 主要终点
- Number of subjects with adverse drug reactions (ADRs)
研究概览
简要总结
The primary objective is to assess the safety profile of YAZ in Chinese women, including adverse drug reactions (ADRs).
The secondary objectives are to investigate the rate of unintended pregnancies, the cycle control for subjects with and without preceding abortion, the bleeding pattern of subjects with and without preceding abortion (including the abortion-related bleeding pattern) and the efficacy in moderate acne vulgaris.
Another objective is to investigate the effect on dysmenorrhea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent
- •Chinese female subjects requesting oral contraception, including subjects who underwent abortion (medical or surgical)
- •Planned use of combined oral contraceptives for at least 6 cycles
- •Age: 18 to 45 years (inclusive); smokers must not be older than 35 years at the time of informed consent
- •At least 4 weeks postpartum for women who are not breastfeeding or after a second trimester abortion
排除标准
- •Evidence or suspicion of incomplete abortion (medical abortion subjects must have complete abortion confirmed by ultrasound [endometrial thickness ≤ 15 mm]).
- •Pregnancy or lactation
- •Menstrual disorders consistent with ovarian failure (eg, oligomenorrhea, amenorrhea, hypomenorrhea)
- •Abuse of alcohol, drugs, or medicine (eg, laxatives)
- •Inability to cooperate with the study procedures for any reason (eg, language comprehension, psychiatric illness, inability to get to the study site).
- •Any diseases or conditions that can compromise the function of body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication
- •Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
- •Any contraindication to YAZ according to the Chinese label, such as:
- •Renal impairment
- •Adrenal insufficiency
- •A high risk of arterial or venous thromboembolic diseases. Examples include subjects who are known to:
- •Have deep vein thrombosis or pulmonary embolism, now or in the past
- •Have cerebrovascular disease
- •Have coronary artery disease
- •Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
- •Have inherited or acquired hypercoagulopathies
- •Have uncontrolled hypertension
- •Have diabetes mellitus with vascular disease
- •Have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35
- •Breast cancer or other estrogen- or progestin-sensitive cancer, now or in the past
- •Liver tumors, benign or malignant, or liver disease
- •Hypersensitivity to any ingredient of the study drug
- •Undiagnosed abnormal genital bleeding
- •Sterilized subjects or concomitant use of other hormonal contraception, intrauterine device (IUD), or intrauterine system (IUS) during the study
- •For subjects qualifying for the moderate acne subgroup:
- •Subjects with acne and atopy, comedonal acne or acne conglobata, sandpaper acne or acne with multiple large nodes, cysts, fistular comedones, or abscessing fistular ducts
- •Use of preparations that have an acne-inducing effect (eg, iodinated or bromated drugs, tuberculostatics, lithium, vitamin B1 [>1.5 mg daily], B6 [>2 mg daily], B12 [>6 µg daily], corticoids, adrenocorticotropic hormone anabolics, quinine, disulfiram, methoxypsoralene, phenobarbital, phenytoin, trimethadione, thyroid depressants, and certain oily cosmetics)
- •Subjects undergoing systemic acne treatment
研究组 & 干预措施
Ethinyl Estradiol 20 (EE20)/DRSP (YAZ, BAY86-5300)
Experimental
Chinese women between 18 and 45 years old inclusive (smokers not older than 35 years old) requesting oral contraception who have no contraindication to YAZ will be recruited for the study. Women who underwent surgical or medical abortions will also be recruited.
干预措施: EE20/DRSP (YAZ, BAY86-5300) (Drug)
结局指标
主要结局
Number of subjects with adverse drug reactions (ADRs)
时间窗: 6 months
次要结局
- Cycle control for subjects with and without proceeding abortion(6 months)
- Number of unintended pregnancies as measured by the Pearl Index (PI)(6 months)
- Number of Acne lesions(6 months)
- Number of bleeding days(Up to 90 days.)
- Number of bleeding episodes(Up to 90 days.)
研究者
相似试验
进行中（未招募）
1 期
Safety, Tolerability, Pharmacokinetics and Immunogenicity Study of GB002 Recombinant Peptide Inhalation Solution in Healthy SubjectsHealthyNCT06423261Zhejiang Echon Biopharm Limited100
已完成
不适用
A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in KoreaDiabetesNCT02779413Novo Nordisk A/S3,303
Unknown
不适用
Arsenic Trioxide in Recurrent and Metastatic Ovarian Cancer and Endometrial Cancer With P53 MutationEndometrial CancerOvarian CancerNCT04489706Ruijin Hospital20
招募中
1 期
To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationNon-small Cell Lung CancerNCT05555212Qilu Pharmaceutical Co., Ltd.72
进行中（未招募）
3 期
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and ExerciseNCT06777238Gan & Lee Pharmaceuticals.274